Cell and Gene Outsourcing

  1. Unlocking Flexible AAV Production With In-House Plasmids, Manufacturing Capacity 5/15/2025

    Discover how 3PBIOVIAN’s advanced plasmid manufacturing and AAVion® platform can drive your AAV program forward by reducing production costs while maximizing efficiency.

  2. Adapting A rcAAV Assay For Commercial Manufacturing 5/15/2025

    Witness how to implement sensitive, cell-based qPCR assays to reliably detect rcAAVs and safeguard the integrity of your rAAV gene therapy manufacturing process.

  3. Engineering The Future Of Lipsomal Drug Delivery 5/14/2025

    Explore our full collection of case studies to discover how liposome technology is transforming drug delivery across a wide range of therapies.

  4. See How We Bring Biotech Innovation To Life! 5/14/2025

    Affinity is the driving force behind everything we do. It's reflected in our deep commitment to our clients, our dedicated teams, and ultimately, the patients who depend on life-changing therapies.

  5. Plasmid DNA Platform 5/14/2025

    Whether your program requires research-grade (RG), high-quality (HQ), or GMP-grade pDNA, we provide scalable manufacturing solutions backed by robust quality control, regulatory expertise, and full traceability.

  6. Microbial Services 5/14/2025

    With decades of hands-on experience in microbial fermentation and a commitment to scientific precision, we’ve built a trusted foundation that continues to drive successful outcomes for our partners.

  7. Mammalian Services 5/14/2025

    Our deep expertise in cell line development, process optimization, and scalable GMP manufacturing ensures high-yield, high-quality protein production tailored to your therapeutic goals.

  8. AAVion® 5/14/2025

    From plasmid design to vial-ready product, our proprietary AAVion® platform streamlines every step to accelerate your AAV program toward clinical success.

  9. What Is The Role Of CROs In Drug Development? 5/13/2025

    CROs are not just facilitators but strategic innovators essential for delivering new therapies to patients efficiently and safely.

  10. Complexing RNPs: Have You Established Your Clinical Acceptance Criteria? 5/13/2025

    When using CRISPR-Cas proteins for gene editing, it’s critical to ensure consistency and quality at each stage of the manufacturing process. The FDA recommends establishing well-defined acceptance criteria for the RNP formation step.